SCHEMBL2847129

SCHEMBL2847129

Nc1nc(NNC(=O)c2ccccc2)c2ccn(CCN3CCN(c4ccc(F)cc4F)CC3)c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 7/20 0.41
HDAC2 Q92769 3/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC3 O15379 1/20 0.40
DRD3 P35462 1/20 0.40
GRM5 P41594 1/20 0.38
HTR7 P34969 2/20 0.37
USP2 O75604 2/20 0.36
TSHR P16473 2/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MEN1 O00255 1/20 0.36
ALOX15 P16050 1/20 0.36
KMT2A Q03164 1/20 0.36
ADRA1D P25100 1/20 0.36
ADRA1A P35348 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2847657 0.88 ADORA2A (0.46) ADORA2A
SCHEMBL2854622 0.82 ADORA2A (0.42) ADORA2AHDAC2HDAC3DRD3GRM5
SCHEMBL2852875 0.79 ADORA2A (0.47) ADORA2AHDAC2HDAC1HTR7ADRA1D
SCHEMBL14922349 0.75 ADORA2A (0.48) ADORA2AALDH1A1MAPTMEN1KMT2A
SCHEMBL8436488 0.75 ADORA2A (0.51) ADORA2AHDAC2HDAC3ADRA1DADRA1A
SCHEMBL14922351 0.73 ADORA2A (0.48) ADORA2AHDAC2HDAC3DRD3HSD17B10
SCHEMBL2847674 0.73 ADORA2A (0.59) ADORA2A
SCHEMBL14922353 0.72 ADORA2A (0.49) ADORA2ADRD3
SCHEMBL8257921 0.71 ADORA2A (0.48) ADORA2AHDAC2HDAC3DRD3ADRA1D
SCHEMBL8259797 0.71 ADORA2A (0.49) ADORA2AHDAC2HDAC3DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723343-B2 Adenosine A2A receptor antagonists KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) 2010-05-25 US disclosed
US-7691869-B2 Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) 2010-04-06 US disclosed
EP-2129220-A2 ADENOSINE A2A RECEPTOR ANTAGONISTS King Pharmaceuticals Research and Development Inc. (US) 2009-12-09 EP disclosed
WO-2008121748-A2 ADENOSINE A2A RECEPTOR ANTAGONISTS KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT,INC. (US) 2008-10-09 WO disclosed
US-20080242672-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2008-10-02 US disclosed
US-20080242673-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242672-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885HDAC2 4153/4885HDAC1 4098/4885
US-20080242673-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885HDAC2 4153/4885HDAC1 4098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.